Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
December 1, 2008

Pluristem Retains KKS for Limb Ischemia Trial

  • Pluristem Therapeutics has contracted KKS for a critical limb ischemia (CLI) multicenter clinical trial utilizing its placental-derived adherent stromal cell product, PLX-PAD.

    KKS will oversee the entire operation and data management of Pluristem's dose escalation, Phase I trial, assessing the safety of PLX-PAD in patients with CLI, at two separate sites in Germany.
     
    KKS Charité (Koordinierungszentrum für Klinische Studien der Charité) is the CRO of the Charité (Charité–Universitätsmedizin Berlin) and conducts all clinical trials for this institution.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.